A Phase 3 interventional study of MCI-186 and Placebo of MCI-186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2007, is one of 8 in phase 3, and was the 1st registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:
National Center of Neurology and Psychiatry, Japan · Sites in Japan
Ages 20+
Regeneron Pharmaceuticals · Sites in Japan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 10
First in 2007; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 136 across the 20 interventional studies, 24 across the 1 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 6 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyotrophic Lateral Sclerosis with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. The objectives of this study are to assess the efficacy and safety of long-term intermittent therapy with 60 mg MCI-186 to ALS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MCI-186
Drug: Placebo of MCI-186
Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
Also known as: Edaravone, Radicut
Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.
Time frame: baseline (seventh cycle) and at 24 week (twelfth cycle)
Number of Participants With Death or a Specified State of Disease Progression
Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.
Time frame: 24 weeks (from seventh cycle to twelfth cycle)
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.
Time frame: baseline (seventh cycle) and at 24 week (twelfth cycle)
Percentage of Participants With Adverse Events
Time frame: 36 weeks (from seventh cycle to fifteenth cycle)
Percentage of Participants With Adverse Drug Reactions
Time frame: 36 weeks (from seventh cycle to fifteenth cycle)
Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group
Time frame: 36 weeks (from seventh cycle to fifteenth cycle)
Percentage of Participants With Abnormal Changes in Sensory Examinations
Time frame: 36 weeks (from seventh cycle to fifteenth cycle)
| Milestone | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Started | 45 | 48 | 88 |
| Completed | 38 | 34 | 72 |
| Not completed | 7 | 14 | 16 |
| Withdrew: Adverse event | 2 | 3 | 2 |
| Withdrew: Physician decision | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 | 5 |
| Withdrew: Tracheotomy due to worsening of als | 1 | 7 | 6 |
| Withdrew: Patient's convenience | 0 | 0 | 1 |
0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.
| units on a scale | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks | -5.5 ± 4.6 | -4.2 ± 4 | -5.4 ± 4.5 |
Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.
| Participants | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| death | 1 | 1 | 1 |
| disability of independent ambulation | 8 | 11 | 20 |
| loss of upper arm function | 3 | 5 | 7 |
| tracheotomy | 0 | 0 | 2 |
| use of respirator | 0 | 1 | 2 |
| use of tube feeding | 1 | 1 | 8 |
To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.
| percentage of FVC | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks | -10.6 ± 13.16 | -12.91 ± 14.97 | -10.54 ± 13.21 |
| percentage of participant | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Percentage of Participants With Adverse Events | 97.8 | 91.7 | 92 |
| percentage of participant | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Percentage of Participants With Adverse Drug Reactions | 4.4 | 10.4 | 10.2 |
| percentage of participant | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| White blood cell count | 11.1 | 4.2 | 10.2 |
| Alanine aminotransferase | 0 | 6.3 | 4.5 |
| Urinary glucose | 0 | 6.3 | 3.4 |
| percentage of participant | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| Numbness | 0 | 0 | 0 |
| Staggering | 0 | 2.1 | 2.3 |
| Vibratory sensation | 0 | 0 | 0 |
Collected over from baseline (seventh cycle) to 36 weeks (fifteenth cycle). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MCI-186 - Placebo of MCI-186 | — | 13/45 (28.9%) | 43/45 (95.6%) |
| MCI-186 - MCI-186 | — | 25/48 (52.1%) | 43/48 (89.6%) |
| Placebo of MCI-186 - MCI-186 | — | 39/88 (44.3%) | 74/88 (84.1%) |
| Event | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| DysphagiaGastrointestinal disorders | 6/45 | 9/48 | 22/88 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 4/45 | 6/48 | 10/88 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/45 | 6/48 | 6/88 |
| Gait disturbanceGeneral disorders | 0/45 | 4/48 | 5/88 |
| DyslaliaNervous system disorders | 1/45 | 0/48 | 6/88 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/45 | 3/48 | 2/88 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 1/45 | 2/48 | 2/88 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/45 | 1/48 | 3/88 |
| PneumoniaInfections and infestations | 0/45 | 1/48 | 2/88 |
| EnterocolitisGastrointestinal disorders | 1/45 | 0/48 | 0/88 |
| Event | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/45 | 10/48 | 28/88 |
| Gait disturbanceGeneral disorders | 9/45 | 10/48 | 27/88 |
| ConstipationGastrointestinal disorders | 8/45 | 10/48 | 20/88 |
| ContusionInjury, poisoning and procedural complications | 7/45 | 3/48 | 8/88 |
| InsomniaPsychiatric disorders | 3/45 | 5/48 | 7/88 |
| PruritusSkin and subcutaneous tissue disorders | 1/45 | 1/48 | 8/88 |
| DiarrhoeaGastrointestinal disorders | 1/45 | 3/48 | 6/88 |
| Tinea pedisInfections and infestations | 3/45 | 3/48 | 4/88 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/45 | 0/48 | 2/88 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 3/45 | 0/48 | 2/88 |
| Age, Categorical(Participants) | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 29 | 62 | 129 |
| >=65 years | 7 | 19 | 26 | 52 |
| Sex: Female, Male(Participants) | MCI-186 - Placebo of MCI-186 | MCI-186 - MCI-186 | Placebo of MCI-186 - MCI-186 | Total |
|---|---|---|---|---|
| Female | 12 | 22 | 31 | 65 |
| Male | 33 | 26 | 57 | 116 |
Ran from Jan 2007 to primary completion in May 2009, 28 months.
Results were first posted in Jun 2018, 9 years after primary completion.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone
Amyotrophic Lateral Sclerosis →